Skip to content
Evigrade
MajorDirect oral anticoagulants (factor Xa inhibitors)×Pharmacokinetic enhancer (booster) for antiretroviral therapy

Updated · Methodology

Mechanism

CYP3A4/5 is the main enzyme that metabolises apixaban in the liver, and apixaban is also a substrate of the transporters P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) (apixaban summary of product characteristics, SmPC, European Medicines Agency, EMA). Cobicistat is a strong CYP3A inhibitor and also inhibits P-gp and BCRP (cobicistat SmPC, EMA). Cobicistat may raise apixaban blood levels and with them the risk of bleeding, although this combination has not been studied on its own (cobicistat SmPC, EMA). For comparison, ketoconazole 400 mg once daily, a strong CYP3A4 and P-gp inhibitor, doubled the area under the concentration-time curve (AUC) of apixaban and raised its peak level 1.6-fold. Such inhibitors can double apixaban exposure, or raise it further in severe renal impairment (apixaban SmPC, EMA). Cobicistat also lowers estimated creatinine clearance because it inhibits tubular secretion of creatinine (cobicistat SmPC, EMA).

Symptoms

The main risk is bleeding: apixaban raises the risk of hidden or overt bleeding in any tissue or organ, which can lead to anaemia (apixaban summary of product characteristics, SmPC, European Medicines Agency, EMA). Common events are nosebleeds, gastrointestinal and gum bleeding, bleeding in the eye, blood in the urine and haematomas. Less common are coughing up blood and bleeding in the brain (apixaban SmPC, EMA). According to the US label, apixaban can cause serious, potentially fatal bleeding (apixaban label, US Food and Drug Administration, FDA).

Management

The combination is not recommended. The EU SmPCs of cobicistat and of its combination tablets with atazanavir, with darunavir and with elvitegravir advise against taking them with apixaban because of the bleeding risk (SmPCs of cobicistat and of these products, European Medicines Agency, EMA). The apixaban SmPC also advises against apixaban in people on systemic treatment with strong inhibitors of CYP3A4 and P-glycoprotein (P-gp), including human immunodeficiency virus (HIV) protease inhibitors (apixaban SmPC, EMA). Cobicistat falls under this rule by its own SmPC. It is a strong CYP3A inhibitor, it inhibits P-gp, and the single-agent product is given only with the protease inhibitors atazanavir or darunavir (cobicistat SmPC, EMA). The US labels allow the combination with a dose reduction. They call for halving an apixaban dose of 5 or 10 mg twice daily and for avoiding the combination in people already taking 2.5 mg twice daily (cobicistat and apixaban labels, US Food and Drug Administration, FDA). Cobicistat lowers estimated creatinine clearance, so take this into account when clearance guides the doses of other drugs (cobicistat SmPC, EMA). In non-valvular atrial fibrillation, the apixaban SmPC lowers the dose to 2.5 mg twice daily in people with two of three features (age 80 years or older, body weight 60 kg or less, serum creatinine 1.5 mg/dL (133 micromol/L) or higher) and in people with creatinine clearance of 15–29 mL/min (apixaban SmPC, EMA). When switching from ritonavir to cobicistat, take care during the first two weeks, especially if the doses of other drugs were adjusted while on ritonavir (cobicistat SmPC, EMA). If apixaban and cobicistat are nevertheless taken together, watch closely for signs of bleeding and stop apixaban in case of severe bleeding (apixaban SmPC, EMA). For adults with life-threatening or uncontrolled bleeding, a specific reversal agent for apixaban, andexanet alfa, is available (apixaban SmPC, EMA).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Apixaban

Other interactions with Cobicistat